Altimmune shares jumped during after-hours trading on Wednesday after the biotech firm said it would disclose top-line ...

About the IMPACT Study The IMPACT (NCT05989711) trial enrolled 212 patients with biopsy-confirmed MASH and fibrosis stages F2/F3 with and without diabetes randomized 1:2:2 to receive either weekly ...

A South Korean biotech’s GLP-1 candidate has reduced liver fat in patients with metabolic dysfunction-associated ...

Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced an oral presentation ...

In June 2025, Carmot Therapeutics Inc. announced a Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of ...

IBI3030 significantly reduces LDL-c (p<0.01 vs. baseline) and Lp(a), improves oral glucose tolerance (OGTT) (effective even in GLP-1R knockout mice), reduces body weight, and preserves insulin ...

Echosens and Boehringer Ingelheim have expanded their collaboration aimed at expediting progress in MASH diagnosis and care.

Zhejiang Doer Biologics Co., Ltd. (Doer Bio), a clinical stage biopharmaceutical company, announces that DR10624, its first-in-class (FIC), tri-specific agonist targeting Fibroblast growth factor 21 ...

It focuses on developing treatments for obesity, metabolic, and liver diseases. ALT’s lead product/candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist, ...

About Altimmune Inc. Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesi ...